With the Nasdaq Biotechnology Index up 65% since the start of the year, it's clear that the biotech sector performed extraordinarily well in 2013 -- but which stocks were the biggest winners? Several small-cap and mid-cap biotech companies posted returns of 200% or more through the middle of December this year, and, in this series, I review the 15 biggest movers.
Let's finish this 2013 review with No. 1 on the list, Gentium (NASDAQ: GENT), which finally won European approval for its long-awaited drug Defitelio in October, helping clear the way for Jazz Pharmaceuticals (NASDAQ:JAZZ) to acquire it for nearly $1 billion in the middle of December.
All in all, the change in Gentium's fortune resulted in more than a 400% return this year, making it the top gainer in my list of the 15 best performing biotechs of 2013.
Complementing Jazz's specialty drug franchise
In a bid to maintain pricing power and reduce competitive threats, drug companies are embracing specialty drug therapies targeting small patient populations with a high unmet need. Jazz has been addressing those markets successfully through both its narcolepsy drug Xyrem and its acute lymphoblastic leukemia drug Erwinaze.
Sales of those two drugs are posting solid growth with Xyram and Erwinaze revenue improving 50% to $153.7 million and 39% to $44.1 million in the third quarter of 2013, respectively.
Jazz's success in building sales for those two drugs likely attracted the company to Gentium's orphan drug Defitelio, which protects vascular cells in cases of severe hepatic veno-occlusive disease, or VOD, a condition that can occur in stem-cell transplant patients.
The condition, which occurs in just one to five of every 10,000 people, is characterized by blocked veins in the liver, has a nearly 90% mortality rate due to liver failure, and typically occurs early on following transplant.
That prognosis and a lack of current treatments means Defitelio offers new hope for a range of patients who will receive the treatment over the course of at least 21 days and for as long as symptoms and signs of VOD exist. That significant unmet need, revenue-friendly dosing schedule, opportunity for global rollout, and chance to leverage Jazz's existing sales force all made Jazz's acquisition attractive to both companies.
The Gentium acquisition also dovetails nicely with Jazz's phase 3 drug Leukotac for graft-versus-host disease. Gentium has been positioning Defitelio as a treatment for graft-versus-host disease and has already received EU orphan designation for the drug for that indication. That suggests Jazz can either build a multidrug product lineup for that indication, develop a combination therapy with the two drugs, or shelve plans for Difitelio for that indication -- effectively removing a potential competitor.
Gentium is also investigating Defitelio in multiple myeloma, a disease affecting plasma cells in the immune system. Jazz's existing drug Erwinaze is already used to treat lymphoid white blood cells in the immune system, suggesting there could be synergies for the pipeline there, too.
Fool-worthy final thoughts
The acquisition is expected to close in the first quarter, which means investors will need to make sure they keep a close eye on Jazz from now on. Jazz likely believes it can win approval for Defitelio in the U.S., where it has fast-track designation. Previously, Gentium had filed for U.S. approval in 2011, but pulled its filing shortly thereafter because the FDA noted deficiencies.
However, with the EU's approval in hand and a more-complete resubmission likely in the first half of next year, FDA regulators could be won over by the end of 2014. If so, the potential opportunity for sales growth tied to approval and label expansion may wind up making Gentium's billion-dollar price tag a bargain for Jazz.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisor's, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.